Decavanadate toxicology and pharmacological activities: V10 or V1, both or none? by Aureliano, M.
Review Article
Decavanadate Toxicology and Pharmacological Activities:
V10 or V1, Both or None?
M. Aureliano1,2
1Faculty of Sciences and Technology, University of Algarve, Campus of Gambelas, 8005-135 Faro, Portugal
2CCMar (Centre of Marine Sciences), University of Algarve, Campus of Gambelas, 8005-135 Faro, Portugal
Correspondence should be addressed to M. Aureliano; maalves@ualg.pt
Received 26 September 2015; Accepted 24 December 2015
Academic Editor: Juan Llopis
Copyright © 2016 M. Aureliano.This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This review covers recent advances in the understanding of decavanadate toxicology and pharmacological applications.
Toxicological in vivo studies point out that V
10
induces several changes in several oxidative stress parameters, different from
the ones observed for vanadate (V
1
). In in vitro studies with mitochondria, a particularly potent V
10
effect, in comparison with
V
1
, was observed in the mitochondrial depolarization (IC
50
= 40 nM) and oxygen consumption (99 nM). It is suggested that
mitochondrial membrane depolarization is a key event in decavanadate induction of necrotic cardiomyocytes death. Furthermore,
only decavanadate species and not V
1
potently inhibited myosin ATPase activity stimulated by actin (IC
50
= 0.75 𝜇M) whereas
exhibiting lower inhibition activities for Ca2+-ATPase activity (15 𝜇M) and actin polymerization (17𝜇M). Because both calcium
pump and actin decavanadate interactions lead to its stabilization, it is likely that V
10
interacts at specific locations with these
proteins that protect against hydrolysis but, on the other hand, it may induce V
10
reduction to oxidovanadium(IV). Putting it all
together, it is suggested that the pharmacological applications of V
10
species and compounds whose mechanism of action is still to
be clarified might involve besides V
10
and V
1
also vanadium(IV) species.
1. Introduction
The number of review papers and chapters reporting deca-
vanadate biochemistry and biological activities has clearly
increased since 2005 [1–5]. Besides the biological activities,
decavanadate (V
10
O
28
6−) as well as other polyoxometalates
(POMs) has a wide range of environmental, chemical, and
industrial uses and applications in catalysis, nanomaterials,
prevention of corrosion, smart glasses, macromolecular crys-
tallography, and food chemistry, among others [6–9].
Decavanadate (V
10
) species are usually not taken into
account in vanadium toxicological studies, although they are
well known to affect the activity of several enzymes and to
impact lipidic structures [1]. Besides, in vivo decavanadate
toxicological studies remain seldom [1, 10]. One eventual
reason is the consideration that almost 98% of vanadium
in cells is present as oxidovanadium(IV), also known as
vanadyl (+4 oxidation state), being the intracellular concen-
tration of vanadium (+5, vanadate) very low to decavanadate
species be formed. Previously, it was described that V
10
was
formed in acidic compartments in Saccharomyces cerevisiae
that were grown in media containing vanadate [11]. It has
been proposed that once formed the rate of decavanadate
decomposition is slow (half-life time of hours) enough to
allow observing its effects not only in vitro [12], but also in
vivo [1, 10]. Furthermore, it was suggested that decameric
vanadate can be stabilized upon interactionwith cytoskeleton
and membrane proteins and therefore its contribution to
vanadium biochemistry and pharmacological activities can
be enlarged [13]. For instance, it was described that rat
adipocytes accumulate much more glucose upon decavana-
date incubation thanwith known insulinmimetic agents such
as bis(maltolato)oxovanadium(IV) (BMOV) [14]. Besides the
insulin mimetic behavior, decavanadate and recent deca-
vanadate compounds show several pharmacological activities
such as anticancer, antibacterial, and antivirus [2, 15–17].
These recent findings, which are now briefly reviewed, are
evaluated and several hypotheses and V
10
modes of action
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through oxidative stress, effects in mitochondria, sarcoplas-
mic reticulum, and cytoskeleton, among other biological and
pharmacological activities are analyzed.
2. Decavanadate and Oxidative Stress
In the last years, our research group has performed novel
in vivo studies with decavanadate in order to understand
the contribution of decameric vanadate species to vana-
dium toxic effects [1, 10]. First, at the specific experimental
conditions, it was confirmed, using spectroscopy method-
ologies, if decavanadate is, or not, completely disintegrated
into vanadate before inducing changes in several stress
markers [1]. Secondly, following decavanadate solutions in
vivo administration it was evaluated and also compared
with monomeric vanadate solutions, several oxidative stress
parameters, namely, reduced GSH content, overall rate of
ROS production, lipid peroxidation, and antioxidant enzyme
activities [1, 10].
First of all, it was concluded that the effects induced by
both vanadate and decavanadate depend not only on the
concentration but also on other experimental parameters
such as the exposure time, cellular fraction, type of tissue,
mode of administration, and species of animal [1, 3, 10].
Secondly, in the majority of the studies decavanadate clearly
induced more, different, and, in many times, opposite effects
than the ones observed for vanadate [3]. Thirdly, oxidative
stress induced by decavanadate may be also due to deca-
vanadate decomposition into vanadate [1, 3]. For instance, it
was observed that the increase in GSH content upon deca-
vanadate exposure was observed in experimental conditions
whereV
10
is almost totally decomposed.The same suggestion
was made for the increase in ROS production, with vanadate
causing a larger increase in the first hour (150%) whereas
decavanadate only caused also an increase (80%) after 12
hours, probably after dissociation into monomeric species
[3].
It is known that the cellular detoxification mechanism
proposed for vanadate involves bioreduction of vanadate to
vanadyl by glutathione (GSH) [18]. Therefore, GSH is an
important cellular antioxidant defense system and directly
or indirectly regulates the levels of ROS [19, 20]. How-
ever, it is proposed that the mechanism for decavanadate
detoxification is not the same, as it was suggested for the
mechanism of thiol compounds oxidation by similar POMs
[21]. Eventually, vanadate reduction byGSHmay be delayed if
decavanadate species are present. Hence, putative differences
in the reactivity towards GSH may explain, at least in part,
the different effects that vanadate and decavanadate solutions
have in GSH levels and in ROS production. In the Fenton-
like reactions vanadate is reduced to vanadyl with production
of O
2
∙− [22]. It is possible that decavanadate participates
in such reactions as well as in the GSH oxidation in a
different manner and/or extension. On the other hand, lipid
peroxidation is commonly described as a consequence of
oxidative damage caused by ROS [19, 23]. It was described
that lipid peroxidation propagation increased by 55% and
80% after 12 and 24 hours, respectively, in liver mitochondria
on exposure to vanadate [1, 3] whereas no increase was
evident after 12 hours in the case of decavanadate exposure.
However, after 24 hours the effect induced by the latter
was the same as that of vanadate [1, 3]. Similar oxidative
stress behavior has been described in cardiac tissue [3],
confirming that decavanadate seems to have a delayed effect
on lipid peroxidation probably due to its decomposition into
vanadate. Furthermore, for longer periods after exposure
(seven days), decavanadate clearly differs from vanadate once
it keeps the levels of lipid peroxidation high [3]. Regarding
the antioxidants enzymes, it was suggested globally that
decavanadate exposition induces a decrease inmitochondrial
antioxidant enzymes activities such as SOD and catalase
activities, whereas opposite or no effects were observed for
vanadate [3]. Therefore, it is suggested that decavanadate
species exposure follows different pathways than vanadate
for the generation of reactive oxygen species and interferes
differently with some of the enzymes involved in antioxidant
defenses in cells. Besides, decavanadate slow decomposi-
tion would also induced delayed oxidative stress responses
through vanadate species.
3. Mitochondria and Decavanadate Toxicity
Vanadium is a pollutant, and its toxic mechanisms are related
to the production of oxidative stress [24]. Mitochondria
provide the majority of the energy produced by aerobic
organisms and are also often referred to as a major ROS
production site. Therefore, mitochondria are a key issue
for decavanadate toxicity and a tool to evaluate changes
in several oxidative stress parameters, as described in the
above section. Several studies pointed out mitochondria
as a potential target for vanadium [25, 26] and variety of
vanadium compounds, that is, vanadyl sulphate (VOSO
4
),
sodiummetavanadate (NaVO
3
), and vanadyl complexes with
organic ligands [27]. Regarding decavanadate in vivo studies,
it was suggested that the mitochondrial fraction tends to
accumulate more vanadium upon decavanadate than upon
vanadate administration, besides inducing different changes
in mitochondrial antioxidant enzymes activities [1, 3]. This
observation was further explored and in vitro studies were
performed using cardiac mitochondria [28]. These studies
showed that decavanadate inhibits mitochondrial respira-
tion and induces mitochondrial membrane depolarization
at nM range of decavanadate concentrations (IC
50
values
40–100 nM) [28, 29]. Decavanadate effects on mitochon-
drial membrane depolarization and oxygen consumption are
about hundredfold more strongly than monomeric vanadate
[28]. The heart mitochondria from the fish (Sparus aurata)
have been shown to be less sensitive to decavanadate than
rat heart mitochondria, with IC
50
values for decavanadate
towards membrane depolarization and oxygen consumption
that were about four times higher (196 and 400 nM, resp.)
than the values found in the rat mitochondria studies (39
and 99 nM, resp.) [3, 28]. One the other side, 𝜇M range of
vanadate concentration is needed to induce the same effects:
IC
50
of 25 𝜇M and 50 𝜇M, respectively, for instance, for fish
heart mitochondria. The effects induced by decavanadate are
not due to the uncoupling of the mitochondria or associated
with themitochondrial permeability transition pore (MPTP),
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Figure 1: Mitochondria: a target for decavanadate (V
10
). Oxygen consumption and membrane depolarization are strongly affected whereas
no effects were found for MTP and ATP synthase. To our knowledge, V
10
effects on Ca2+ uniporter and Na+/Ca2+ exchanger were not yet
described. F
1
F
0
, F
1
F
0
-ATP synthase; e.t.c., electron transport chain; mCU, Ca2+ uniporter; NCx, Na+/Ca2+ exchanger; MTP, mitochondrial
transition pore; Ψ
𝑚
, membrane potential.
once the respiratory rate control was not changed or the
inhibitor cyclosporine did not prevent effects induced upon
decavanadate incubation.
Once the hypothesis that V
10
affects respiratory com-
plexes I and II is excluded, we considered the possibil-
ity that decameric vanadate may interfere with complex
III (ubiquinol : cytochrome 𝑐 oxidoreductase). The observed
changes in the absorbance at 500–550 nm (0.05OD increases)
upon incubation with V
10
pointed out that the cytochrome 𝑏
redox state is altered and suggested that complex III is shifted
to a more oxidized steady-state. Thus, decavanadate (20𝜇M
total vanadium concentration, i.e., decavanadate) affects the
redox state of complex III cytochrome 𝑏, similarly as the well-
known respiratory inhibitor antimycin-A [3, 28, 29]. With
a similar total concentration of vanadate (20𝜇M) no effect
was observed [28, 29]. Notice that the respiratory rate control
was not changed for either rat or fish heart mitochondria
in the presence of either vanadium solution (5.0 ± 0.1) nor
did the ADP/O values for pyruvate or malate; the vanadate
solutions do not induce uncoupling of the mitochondria
[28]. Furthermore, 2 𝜇M decavanadate did not affect NADH
content, FoF1-ATPase, and cytochrome 𝑐 oxidase, nor did
it affect respiratory complexes I and II, pointing out to a
specific V
10
interaction with complex III (cytochrome 𝑏)
from mitochondrial respiratory chain [3, 28]. The V
10
effects
can be summarized in the scheme present at Figure 1. By
inducing mitochondria membrane depolarization and/or by
inhibiting mitochondria respiratory chain, it is expected
that V
10
prevents the production of anion superoxide. In
fact, both V
10
-induced mitochondrial depolarization and a
decrease of mitochondrial superoxide anion generation can
themselves account for a V
10
antioxidant effect. A potential
role for decavanadate in accepting electrons instead of oxygen
is suggested. Conversely, V
10
interaction with complex III
would induce a leakage of electrons to molecular oxygen; it
would be expected to induce the production of ROS.
Recently, the formation of vanadyl species upon
decavanadate incubation with mitochondria (unpublished
results), as analyzed by EPR, was observed, whereas no
signals were detected upon vanadate incubation. It has been
described previously that decavanadate may interact with
NADH oxidation by oxygen catalyzed by several enzymes
present in membrane systems such as the plasma membrane
of red blood cells or rat liver microsomes that leads to
reduction of cytochrome 𝑐 [30] and to vanadate reduction.
In other studies, decavanadate has been described to be
reduced by a specific isocitrate dehydrogenase pointing out
to a redox role for decavanadate [31].These studies suggest an
increasing of NADH oxidation by decavanadate, consequent
oxygen reduction to H
2
O
2
, and concomitant reduction to
vanadyl species [30, 31].
4. Decavanadate Toxicity Induces
Apoptosis or Necrosis?
Vanadium causes a variety of toxic effects such as hema-
tological and biochemical changes [10, 32]. Several studies
have shown vanadate effects varying from stimulation of
cell growth to induction of cell death [3, 20, 24, 32, 33].
In most cases, the vanadate effect on cell proliferation was
biphasic, being cytotoxic for cells over a concentration range
of 50 to 100 𝜇M[34]. By targetingmitochondria decavanadate
might induce directly or indirectly processes of cell death.
Besides, the inhibition of themitochondrial respiratory chain
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described above by decavanadate can lead to sustained mito-
chondrial depolarization which is lethal for cells demanding
a high supply of metabolic energy. Mitochondria are well-
known organelle responsible for many features and processes
of cell death, such as apoptosis and necrosis, and calcium
homeostasis. Cell death is of course a parameter of toxicity
and therefore questions arise: did the decavanadate toxicity
effects induce cell death? In which way? The answer can be
found on the studies that described that, upon incubation for
24 hwith either decavanadate or vanadate, the concentrations
were found to produce 50% loss of cell viability (1 𝜇M V
10
,
and 10 𝜇M, resp.). Both vanadate species induce cardiomy-
ocytes necrotic cell death, whereas no significant caspase-3
activation was observed [29]. It was also observed that the
concentration needed for 50% mitochondrial depolarization
was 0.65𝜇M for V
10
and 6.5𝜇M for V
1
, that is, only slightly
lower than the value obtained for vanadate induced 50%
loss of cell viability [29]. Furthermore, depolarization of
mitochondria was clearly observed even from 6 hours after
addition of decavanadate to cardiomyocytes, suggesting a
leading role of mitochondrial depolarization in V
10
-induced
cardiomyocytes death and pointing out as an early event in
decavanadate induced necrotic cell death of cardiomyocytes.
It is known that mitochondrial membrane depolarization
leads to mitochondrial calcium release [35] and also IP
3
-
mediated endoplasmic reticulum release in cardiomyocytes
[36]. In fact, it was observed that the incubation of both
decavanadate and vanadate with cardiomyocytes induces a
rise of the basal cytosolic Ca2+ from 60 ± 10 nM to 200–
250 nM, upon 24 h incubation with 1 𝜇M V
10
or 10 𝜇M V
1
[29].These results are in agreement with earlier studies show-
ing that vanadate increased intracellular Ca2+ in cultured
aortic smoothmuscle cells, thereby affecting the vascular tone
[37]. In the heart, the release of Ca2+ from intracellular stores
leads to an increase of heart rate and cardiac inotropism and
to vasodilatation [36–38]. Thus, it is strongly suggested that
mitochondrial membrane depolarization is a key event in
decavanadate induced cardiomyocytes death. As referred to
above, the effects described for decavanadate, after 24 hours
of incubation, may be due to vanadate upon decavanadate
slow decomposition.
5. Sarcoplasmic Reticulum and Decavanadate
Sarcoplasmic reticulum (SR) plays a crucial role in calcium
homeostasis and in regulating the process of muscle contrac-
tion. SR Ca2+-ATPase is known to be responsible for actively
transporting calcium ion, at ATP expenses, into SR lumen,
and it plays a major role in the muscle relaxation process.
The high sensitivity of the sarco/endoplasmic Ca2+-pumps
to vanadate is well documented [39] providing also a simple
explanation for the sustained rise of basal cytosolic Ca2+ con-
centration after incubation with vanadate and decavanadate
solutions, as described above. However, it was demonstrated
more than twenty years ago that decameric vanadate has
specific features and interactions with SR Ca2+-ATPase, for
instance, by inducing protein crystallization [40]. Besides,
it was described that only decavanadate is able to inhibit
SR Ca2+-ATPase calcium uptake, whereas no effects were
observed for V
1
[41]. Using several different methodologies,
it was suggested that decavanadate interaction with the Ca2+-
ATPase is noncompetitive versus ATP and that it inhibits
strongly the ATPase activity (IC
50
= 15 𝜇M), in comparison
with V
1
(IC
50
= 80 𝜇M) [12, 39]. In the absence or in the
presence of the natural ligand ATP, the interaction of V
10
with the pump induces vanadate reduction, as analyzed using
EPR spectroscopy [42]. During these studies, protein cysteine
oxidation was detected upon V
10
incubation, suggesting the
involvement of cysteines at the V
10
binding site as well
as the participating of vanadyl species on the process of
enzymatic inhibition. It is well established that the V
10
binding site, which is formed by three proteins domains [43],
is located at the cell cytoplasm side. V
10
can interact with
proteins by electrostatic interaction or by hydrogen bonding
but the specific residues involved in V
10
-SR Ca2+-ATPase
interaction, perhaps a cysteine residue, are yet to be totally
clarified.
Once decavanadate binding site is located at the cytoplas-
mic site, V
10
species would need to cross the SR membrane
in order to bind to the E1E2 ATPase. Whereas the interaction
between V
1
and the E1E2 ATPase is only favored by the
E2 conformation, V
10
binds with all the two conformations
E1 and E2, been or not phosphorylated, thus interacting
also with E1P and E2P [12]. Therefore, it is suggested that
decavanadate can affect all the steps of the mechanism of
calcium translocation by the E1E2 ATPase. Perhaps due
to this particularity, V
10
interaction with the ion pumps
might also occur through the extracellular side, as is the
case with several other drugs that impact these proteins
[3]. By targeting ion pumps without needing to cross the
membrane, decavanadate can more rapidly induce changes
in calcium homeostasis with implications in, for example,
muscle contraction, calcium accumulation in mitochondria,
and concomitantly ROS production and cell death.
Studies with the SR Ca2+-ATPase were also performed
upon decavanadate in vivo intravenous administration [1,
3]. Thus, measurements of the skeletal muscle SR Ca2+-
ATPase activity, performed 48 hours upon administration
of decavanadate (70.4 ± 6.65 nmol Pi/min/mg), showed that
the ATP hydrolysis is significantly increased (52%), whereas
vanadate solution exposure decreased it by 15%.These results
seem in opposition to previously decavanadate and vanadate
inhibition studies performed in vitro with the SR Ca2+-
ATPase pump. It is difficult to explain why the sarcoplasmic
reticulum vesicles prepared from animals previously exposed
to V
10
present higher ATPase activity and are opposite to
the ones observed for vanadate. Vanadate is known for
its ability to increase the contractile force of heart muscle
through its inotropic effect [37, 38, 44]. Apparently, V
10
affects differently the calcium homeostasis and the samples
used contain more calcium or V
10
interaction would induce
the formation of ATPase dimers, eventually relevant for
ATPase activity.These very interesting observations that need
further studies point out that different responses obtained
upon in vivo administration cannot be always associated with
in vitro studies and prove that great care must be taken with
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extrapolations from in vitro to in vivo conditions and vice
versa.
6. Decavanadate and Muscle Contraction
Several recent review papers clearly point out that deca-
vanadate presents many biological activities affecting several
biological processes and biochemical mechanism including
themechanism ofmuscle contraction and its regulation [1, 3].
Skeletal muscle cells and vanadium are historically strongly
connected to each other, since vanadium was identified as an
impurity in commercial ATP prepared from equine muscle
[45]. However, the essentiality of vanadium in muscle and
globally in humans is yet to be clarified [46]. Myosin, the
major ATPase of muscle, interacts with actin during the
process of muscle contraction. Although some aspects are
poorly understood, during the contractile cycle, the rate
limiting step of the ATP hydrolysis is the release of Pi from
myosin, which is accelerated by the rebinding of actin [47].
It has originally demonstrated that, in the absence of actin,
vanadate inhibitsmyosinATPase activity [48]. However, only
decavanadate inhibits myosin ATPase activity stimulated
by actin [49]. A simple mechanism for the experimentally
observed noncompetitive inhibition pattern of V
10
towards
both ATP and actin, as it does not interfere with the
nucleotide binding site or with actin binding surface, is by
acting as a “back-door” blocking the actomyosin cycle, most
likely, in the prehydrolysis state [1, 49, 50].
When we compare the effects of decavanadate on myosin
ATPase, Ca2+-ATPase, actin polymerization, and myosin
ATPase activity stimulated by actin, the latter presented
the higher decavanadate inhibitory capacity with an IC
50
value of 0.75𝜇M, whereas higher inhibitory IC
50
values
were found for Ca2+-ATPase activity (15 𝜇M) and for actin
polymerization (68𝜇M) [3, 12, 13, 49]. It was suggested that
skeletal muscle myosin contains a high affinity decavanadate
binding site, being a potential target for decavanadate [49].
Recent studies also described a specific decavanadate
interaction with the actin monomer, G-actin, at the ATP
binding site [3, 50]. Actin is one of the most abundant pro-
teins in cells, being involved in many cellular and biological
processes. It has been described that vanadium induces actin
cytoskeleton damage associated with impaired fertility [51].
However, the studies about “vanadium and actin,” and more
specifically with “decavanadate and actin,” remain scarce [1,
3, 50]. As it was above described for the V
10
-SR Ca2+-ATPase
interaction, also the decavanadate interaction with G-actin
leads to cysteine oxidation and vanadyl formation, whereas
no reductions were observed upon vanadate incubation [1, 3].
In contrast to the calcium pump, ATP prevents the formation
of vanadyl species, confirming that V
10
binds to the ATP
binding site. Both decavanadate and vanadyl inhibit actin
polymerization. It was further observed that actin contains
a high affinity binding site for vanadyl, as it happens with
other proteins such as transferrin and albumin. Therefore,
it is suggested that, in the absence of ATP, decavanadate
interactions with actin lead to vanadyl protein binding,
although the mechanism by which decavanadate inhibits
actin polymerization, for instance, through vanadyl forma-
tion, is yet to be clarified.
7. Decavanadate Pharmacological Activities
The majority of the studies described above support the
concerns over the potential risk of the use of vanadyl sulphate
in athletes as a sport supplement [44]. In fact, once vanadium
is slowly eliminated from mammalian tissues [52], chronic
consumption of vanadium compounds, such as vanadyl
sulphate, may eventually reach the toxic levels to cardiomy-
ocytes. Furthermore, decavanadate, vanadate, or vanadyl
interferes, although differently, withmuscle proteins andwith
the process of muscle contraction and its regulation. The
processes by which vanadyl compounds, commonly used by
the bodybuilders, increase muscle mass and enhance muscle
power are not understood. In fact, the biochemical processes
involved whether being related with muscle bioenergetics,
metabolism, and functionality of the contractile systems
or through the increasing of the muscle fibers is almost
completely unknown. The role of vanadium in muscle cells
and its essentiality to humans still remains a mystery.
Regarding the use of vanadate species as anticancer agents
and in the chemotherapy of multidrug-resistant tumors, also
the studies described above might be in contradiction with
this possibility due to its toxic effects, being manifested even
at very low concentrations.Nevertheless, as described briefly
below, the pharmacological activities of decavanadate, and
decavanadate compounds as antidiabetic, antivirus, antibac-
terial, and antitumor agents, is actually a matter of increasing
interest.
For V
10
alone, it was reported that rat adipocytes
incubated with decavanadate at 37∘C, thus favoring V
10
decomposition, accumulate much more glucose than with
other known insulin mimetic agents such as BMOV or
vanadate [13]. It is suggested that the agents (enzymes,
receptors, pumps, or channels) involved in the early events
of the process of glucose transport can be enhanced and/or
potentiated by V
10
. However, to our knowledge, the V
10
mechanism or contribution as an insulin mimetic agent or
enhancer is yet to be totally clarified. Eventually, as it was
referred for vanadate, decavanadate insulin mimetic effects
are probably induced through the inhibition of tyrosine
phosphatase (PTP) [53]. Moreover, it was speculated that V
10
could have a role in treating Leishmania diseases through
PTP inhibition [53]. Another mechanism includes the use
of decavanadate compounds as a prodrug of peroxovanadate
insulin mimetics [54]. Crystallization of decavanadate in a
spatially selective manner within the protein cages of virions
is the most cited paper regarding V
10
in biology [17]. As
it was described in a fundamental review, the antiviral and
antitumor activities are the dominant activities of POMs
in pharmacology and medicine [55]. It seems that POMs
such as decavanadate are able to inhibit the virus activities
by preventing the virus-cell host binding [56]. POMs low
toxicity toward human body and their high solubility in water
are main factors that contributed to their development as
drugs.
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A chitosan-decavanadate complex with antibacterial
activity against Escherichia coli and Staphylococcus aureus
was recently described [57]. Chitosan is famous for its
antimicrobial activity as it inhibits the mRNA synthesis after
penetration into the nuclei of the microorganism. On the
other hand, decavanadate is known for its inhibition of
ion pumps causing a disturbance in the molecular trans-
port across the membrane thus devastating the bacteria
metabolism, presenting altogether an antibacterial inhibi-
tion of 12.5 𝜇M. The antitumour activity of decavanadate
is less understood and more recent than the antiviral one.
New decavanadate complexes have been synthetized and
tested their antitumor activity in vitro against human lung
carcinoma cells (A549) and murine leukaemia cells (P388)
[58]. Both compounds exhibited lower inhibition than cis-
platin compounds, whereas the decavanadate compound
with a higher lipophilic effect, thus enhancing its penetration
through the lipid bilayer of the cellmembrane, showed higher
inhibitory activity [58]. The cytotoxicity of both V
10
com-
pounds was tested on human normal hepatocytes beingmore
or equally toxic against normal cells compared to effective
against cancer cells. Other decavanadate complexes were
reported as antitumor agents, showing apoptotic mechanism
of cell death and also lower activities than platin compounds
[15, 16, 58].
Although the antitumor activity of V
10
compounds
against a large number of tumor cells has been reported, it
looks as if their mechanisms of action are still difficult to
understand. It was described that polyoxometalates are able
to inhibit the tumor growth by inducing apoptosis. Some
studies suggest that POMs entered into the mitochondrion
leading to the inhibition of ATP synthesis [55]. Although it
is speculated that V
10
effects in mitochondria can be applied
for other POMs, these studies are apparently in opposition
with the studies described above regarding the process of cell
death induced by decavanadate in cardiomyocytes.
Notice that, in the majority of the studies described
above, the stability of decavanadate compounds, at the several
experimental conditions, was not performed or takes in
consideration its putative reduction or decomposition into
vanadate species. As described above, although decavanadate
toxicological and pharmacological applications differ from
vanadate, we cannot exclude a participation of monomeric
vanadate. Furthermore, decavanadate toxicity effects and
pharmacological activities can be due, at least in part, to
V
10
reduction to vanadyl species. Therefore, although some
decavanadate compounds have been shown to be stable, care
must be taken before attributing them the toxicity effects or
the pharmacological activities [1, 3].
It is known that abnormal levels of alkaline phosphatases
(ALP) in the serum are detected in cancer patients since
tumors are abnormal cellular growth proliferating faster
than a normal cell. Inhibition of ALP will affect tumor cell
metabolism and function and therefore POMs were assessed
for their inhibitory effect on ALP activity and as putative
antitumor agent [59]. V
10
also demonstrated inhibition on
several alkaline phosphatases, suggesting that decavana-
date, similarly to other POMs, inhibits abnormal cellular
growth proliferating. Despite promising results against virus,
bacteria, and tumor cells, polyoxometalates and V
10
are
not yet tested in clinical trials. This may be due to the
lack of understanding of its mechanism of action. Besides,
to be approved as a drug the polyoxometalate or the V
10
compoundsmust showhigher activity against tumor cells and
very low toxicity toward normal cells.
8. Conclusions
Oxidative stress induced by decavanadate would occur in
organisms more often than expected. Decavanadate mecha-
nisms to induce stress might involve the interaction with ion
pumps, mitochondria, and specific biochemical processes.
The mechanism of necrotic cell death induced by deca-
vanadate is proposed to be mediated through mitochondrial
membrane depolarization. The simultaneous effects in ion
pumps and in mitochondria promoted by decavanadate
lead to an intracellular calcium increase, changes in ROS
producing, and inhibition on antioxidant enzymes activities,
namely, SOD and catalase. Several major proteins in muscle
contraction and its regulation are molecular targets for
decavanadate. Particularly interesting is the proposed back-
doormechanism ofV
10
myosinATPase inhibition stimulated
by actin and also the inhibition of actin polymerization by
decavanadate, although the latter process is still to be clari-
fied. Somedecavanadate compounds seemnot suited for anti-
tumour activity since their cytotoxicity was higher than its
inhibitory rate of tumor cell growth. However, decavanadate
was used with success in antibacterial activity and described
to present many other pharmacological applications such
as antidiabetic agent besides against virus activities. Putting
it all together, it is proposed that the understanding of
decavanadate toxicology and pharmacological activities may
be useful, at least in part, to elucidate the biological activities
of several polyoxometalates in order to make them available
and safe for clinical use.
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